Key facts
- It has raised $13.8M; the latest was Early Stage VC ($13.8M) in Feb 2025.
- Notable investors include Shanghai Healthcare Capital, Shanghai Guofang Private Equity Fund Management Company, Jiangbei Investment Group, Shangshi Venture Investment, GP Capital (Shanghai) — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Juvensis Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Juvensis Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Juvensis Therapeutics
Developer of gene therapy drugs designed for promoting recovery of myocardial function. The company's product is based on an innovative mechanism of energy metabolism regulation. The developed telomere protection protein can block the vicious cycle of telomere damage-mitochondrial dysfunction, providing differentiated and accessible gene therapy products for clinical refractory and degenerative diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Juvensis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Juvensis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Juvensis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.